Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: DKK 309.1B (to FY2025). Net income: DKK 102.4B, trailing twelve months to FY2025. Free cash flow: DKK 59.0B, trailing twelve months to FY2025. Operating margin: 41%, trailing twelve months to FY2025.

NVONovo Nordisk A/S

Healthcare

$38.62-35% 1Y

$38.62

$34.7652 weeks$61.72

NVO as reported

Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +6.4% on the year before. 10 reported series are charted on this page, each one as filed.

DKK 309.1B

Revenue, trailing twelve months · to FY2025 · +6.4% against the twelve months before

Net income: DKK 102.4B
Net income · +1.4% year on year · trailing twelve months to FY2025
Free cash flow: DKK 59.0B
Free cash flow · −20% year on year · trailing twelve months to FY2025
Operating margin: 41%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for NVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	DKK 309.1B	+6.4%	FY2025
Net income	DKK 102.4B	+1.4%	FY2025
EPS	DKK 23.03	+1.8%	FY2025
Gross margin	81%	n/a	FY2025
Operating margin	41%	n/a	FY2025
Net margin	33%	n/a	FY2025
ROE	53%	n/a	FY2025
ROA	19%	n/a	FY2025
ROIC	33%	n/a	FY2025
Free cash flow	DKK 59.0B	−20%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.